EC Number   |
Inhibitors |
Structure  |
|---|
    3.5.4.4 | more |
no inhibition by erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride |
 |
| 3.5.4.4 | more |
structure-based design, synthesis, and structure-activity relationship studies of non-nucleoside adenosine deaminase inhibitors, overview |
|
| 3.5.4.4 | more |
molecular dynamic simulations of inhibitor-enzyme interaction, overview |
|
| 3.5.4.4 | more |
loss of activity precedes the global secondary and tertiary structure transition when the enzyme is exposed to denaturant, structural mechanism, overview |
|
| 3.5.4.4 | more |
no inhibition of the bovine enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin |
|
| 3.5.4.4 | more |
no inhibition of the human enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin |
|
| 3.5.4.4 | more |
cytotoxic effects of inhibitors against human breast cancer cell lines MCF-7 and MCF-10A |
|
| 3.5.4.4 | more |
ADA1 activity is not changed significantly by aspirin, metoprolol, isosorbide mononitrate, and molsidominemolsidomine; molsidomine does not influence plasma adenosine deaminase activity significantly |
|
| 3.5.4.4 | more |
the trend of relative activity is directly proportional to helicity and inversely proportional to accessible surface area |
|
| 3.5.4.4 | more |
strong inhibition by the traditional Chinese medicines Rhizoma Chuanxiong and Angelica sinensis |
|
